On the rationale of the alpha-hydroxybutyrate dehydrogenase (HBD) determination.
The discriminating power of HBD, LD and of the HBD/LD ratio in comparison with LD1/LD2 and LD5/LD4 ratios in acute myocardial infarction and hepatic disease is evaluated. The results demonstrate that there are no clinical reasons for the determination of the HBD when a method using the conditions of the Committee of Enzymes of the Scandinavian Society for Clinical Chemistry (SCE) is used.